Pharmacokinetic behavior of amikacin in 31 Iranian critically ill septic patients

Daru

Volumn 10, Issue 3, 2002, Pages 111-119

  Sabzghabaee, Ali Mohammad ^a,b   Mojtahedzadeh, Mojtaba ^a   Tajerzadeh, Hosnieh ^a   Asasi, Nazila ^a   Ganji, Mohammadreza ^a   Mohagheghi, Abbas ^a   Gholami, Kheirollah ^a   Hadavand, Naser ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amikacin; Critically ill patient; ICU; Pharmacokinetics; Sepsis

Indexed keywords

AMIKACIN; CREATININE; SERUM ALBUMIN;

ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICAL ILLNESS; CROSSOVER PROCEDURE; DIALYSIS; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; IRAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MALE; MEASUREMENT; MEDICAL RECORD; PROSPECTIVE STUDY; SEPSIS;

EID: 0036932416     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Moore, R.D., Smith, C.R., Leitman, P.S. (1984) The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacterimia. J. Infect. Dis. 149:443-448.
2. Moore, R.D., Leitman, P.S., Smith, C.R. (1987) Clinical response to aminoglycoside therapy concentrations. J. Infect. Dis. 155:93-99.
3. Isaksson, B., Nilsson, L., Malleer, R., Soren, L. (1988) Post-antibiotic effect of aminoglycosides on gram negative bacteria evaluated by a new method. J. Antimicrob. Chemother. 22:23-33.
4. Garrafo, R., Iliadis, J.P., Cano, P., Dellamonica, P., Lapalus, P. (1989) Application of bayesian estimation for the prediction of an appropriate dosage regimen of Amikacin. J. Pharm. Sci. 78:753-757.
5. Myagawa, C.T. (1993) Aminoglycosides in the intensive care units: An old drug in a dynamic environment. New Horizons. 2:172-180.
6. Bodenham, A., Shelly, M.P., Opark, G.R. (1988) The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin. Pharmacokinet. 14:347-373.
7. Klotz, U., (1976) Pathophysiological and disease-induced changes in drugs distribution volume: Pharmacokinetic implications. Clin. Pharmacokinet. 1:204-218.
8. Sawchuk, R.J., Zask, D.E. (1976) Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions. J. Pharmacokinet. Biopharm. 4:183-195.
9. Bone, R.C., Fisher, C.J., Clemmer, T.P.(1989) Sepsis syndrome, A valid clinical entity. Crit. Care. Med. 17:389-393.
10. Bone, R.C., Balk, R,A., Cerra, F.B., Dellingere, R.P., Fein, A.M., Knaus, W.A., Schein,r.m., Sibald, W.J., (American College of Chest Physicians/Society of Critical Care Medicine consensus conference) (1992) Definitions for sepsis and organ failure and guidelines for Innovative therapies in sepis. Crit. Care Med. 20:864-874
11. Knaus, W.A., Draer, E.A., Wanger, D.P., Zimmerman, J.E. (1985) APACHE II: A severity of disease classification system. Crit. Care Med. 13:818-829.
12. rd Ed., Applied Therapeutics Publications, Vancouver, pp: 14:(1-47).
13. Devine, B.J. (1974) Gentamicin therapy. Drug Intell. Clin. Pharm. 8:650-655.
14. Sheiner, L.B., Beal, S.L. (1981) Some suggestions for measuring predictive performance. J. Pharmacokin. Biopharm. 9(4):503-512.
15. Sheiner, L.B., Beal, S.L. (1982) Erratum (some suggestions for measuring predictive performace) J. Pharmacokinet. Biopharm. 10 (2):229.
16. Debord, J., Voultoury, J.C., Lachatre, G., Favereau, J.P., Gay, R. (1992) Population pharmacokinetic parameters for bayesian monitoring of Amikacin therapy in intensive care unit patients. Eur. J. Clin. Pharmacol. 43:435-436.
17. Bressolle, F., Gouby, A., Martinez, J., Joubert, P., Saissi, G., Guilloud, R., Gomeni, R. (1996) Population pharmacokinetics of Amikacin in critically ill patients. Antimicrob. Agents Chemother. 40:1682-1688.
18. Fdez de Gatla, M.M., Mendez, M.E., Romans, S., Clavo, M.V., Dominguez-Gil, A., Lanao, J.M. (1996) Pharmacokinetics of Amikacin in intensive care unit patients. J. Clin. Pharm. Ther. 21:417-421.
19. Chelluri, L., Jastremski, M.S. (1987) Inadequacy of standard aminoglycoside loading dose in acutely ill pati'ents. Crit. Care. Med. 15:1143-1145.
20. Chelluri, L., Warren, J., Jastremski M.S. (1989) Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramicin in critically ill patients. Chest 95:1295-1297.
21. Pleasants., R.A., Dupuis, R.E., Crass, R.E. (1986) Patient-location specific alterations in aminoghycoside volume of distribution. Clin. Pharm. 5:872-873.
22. Triginer, C., Izquierdo, I., Fernandez, R., Rello, J., Torrent, J., Benito, S. (1990) Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 16:303-306.
23. Sampliner, R., penier, D., Powell, R., Finley, P. (1984) Influence of ascites on tobramicin pharmacokintics. J. Clin. Pharmacol. 24:43-46.
24. Dasta, J.F., Armstrong, D.K. (1988) Variability of aminoglycoside pharmacokinetics in critically ill surgical patients. Crit. Care Med. 16:327-330.
25. Bauer, L.A., Blouin, R.A., Griffen, W.O., Record, K.E., Bell, R.M. (1980) Arnikacin pharmacokinetics in morbidly obese patients. Am. J. Hosp. Pharm. 36:519-522.
26. Bauer, L. A., Edwards, W.A.D., Dellinger, E.P., Simonowitz, D.A. (1983) Influence of weight on aminoglycoside pharmacokinetics in critically ill surgery patients. Eur. J. Clin. Pharmacol. 24:643-651.
27. Blouin, R.A., Bovwer, K.L.R., Record, K.E., Griffen. W.O., Plezia, P.M., John, W. (1985) Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-by pass surgery. Clin. Pharm., 4:70-72.
28. Zarowitz, B.J., Pilla, A.M., popovich, J. (1990) Expanded gentamicin serum level monitoring role in ICU. Clin. Pharmacokinet. 9:40-44.
29. Oparaoji, E.C., Cornwell, E.E., Hekmat, E., Cheong, R.L., Adir, J.S., Siram, S. (1993) Aminoglycoside's volume of distribution in postoperative patients with septic shock. Clin. Pharm. 12:131-134.
30. Kloth, D.D., Tegtmeier, B.R., Kong, C., Akahoshi, M.P., Leach, S.H., Beatty, J.D. (1985) Altered gentamicin pharmacokinetics during the perioperative period. Clin. Pharm. 4:182-185.
31. Zaske, D.E. (1980) Gentamicin dosage requirements: Wide interpatient variation in 242 surgery patients with normal renal function. Surgery 87:164-170.
32. Martin, C., Mallet, M.M., Saux, P., Bruguerolle, B., Heart, V., Gouin, F. (1988) Tobramicin dosing in mechanically ventilated patients: Inaccuracy of a" rule of thumb". J. Antimicrob. Chemother. 22:505-511.
33. Triginer, C., Fernandez, R., Izquierdo, I., Rello, J., Benito, S. (1989) Pharmacokinetic changes related to mechanical ventilation (lertter). DICP Ann. Pharmacother. 23:923-924.
34. Berry, A.J. (1981) Respiratory support and renal function. Anesthesiology 55:655-667.
35. Richard, C.c Bendeux, A., Delian, F. (1986) Effect of mechanical ventilation on hepatic drug pharmacokinetics. Chest 90:837-841.
36. Perkins, M.W., Dasta, J.F., Dellaven, B. (1989) The physiological implications of mechanical ventilation on pharmacokinetics. DICP 23:316-323.
37. Lugo, G., Castaneda-Hernandez, G. (1997) Relationship between hemodynamic and vital support measures and pharmacokinetic variability of Amikacin in critically ill patients with sepsis. Crit. Care Med. 25:806-811.
38. Watling, S.M., Dasta, J.F. (1993) Aminoglycoside dosing considerations in intensive care unit patients. Ann. Pharmacother. 27:351-357.
39. Dorinsky, P.M., Gaded, J.E. (1989) Mechanisms of multiple non-pulmonary organ failure in ARDS. Chest 96:885-892.
40. Pinsky, M.R., Vincent, J.L., Deviere, J. (1993) Serum cytokine levels in human septic shock: Relationship with multiple system organ failure and mortality. Chest 103:565-575.
41. Marik, P.E. (1993) Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth. Intensive Care 21:172-173.
42. Zaske, D.E., Strate, R.G., Kohls, P.R. (1991) Amikacin pharmacokinetics: Wide interpatient variation in 98 patients. J. Clin. Pharmacol. 31:158-163.
43. Zaske, D.E., Cipolle, R.J., Rotschafer, J.C., Kohls, P.R., Strate, R.G. (1991) Individualizing Amikacin regimens: An accurate method to achieve therapeutic concentrations. Ther. Drug Monit. 13:502-506.
44. Rodvold, K.A., Zofuka, H., Rotschaper, J.C. (1988) Aminoglycoside pharmacokinetic monitoring: An integral part of patient care? Clin. Pharm. 7:608-613.
45. Mann, H.J., Fuhs, D.W., Cerra, F.B. (1987) Pharmacokinetics and pharmacodynamics in critically ill patients. World J. Surg. 1:210-217.
46. Zaske, D.E., Bootman, J.L., Solem, L.B., Strate, R.G. (1982) Increased burn patient survival with individualized dosages of gentamicin. Surgery 91:142-149.
47. Kirby, M.G., Dasta, J.F., Armstrong, D.K., Tallman, R. (1986) Effect of low-dose dopamine on the pharmacokinetics of tobramycin. Antimicrob. Agents Chemother. 29:168-170.
48. Gyselynck, A.M., Forrey, A., Cutler, R. (1971) Pharmacokinetics of gentamicin: Distribution and plasma renal clearance. J. Infect. Dis. 124 (Suppl): 570-576.
49. Barza, M. (1975) Predictability of blood levels of gentamicin in man. J. Infect. Dis. 132:165-174.
50. Kaye, D. (1974) The unpredictability of serum concentrations of gentamicin: Pharmacokinetics of gentamicin in patients with normal and abnormal renal function. J. Infect. Dis. 130:150-154.